Kyowa Kirin Co., Ltd.
4151
Kedudukan dalam Saham
#2444
Operating globally, Kyowa Kirin Co., Ltd. is a pharmaceutical company focused... Operating globally, Kyowa Kirin Co., Ltd. is a pharmaceutical company focused on the discovery, development, manufacturing, and marketing of innovative medical therapies. The company's core areas of expertise span oncology, nephrology, central nervous system disorders, and immunology. Its extensive product portfolio includes established medications such as ABSTRAL, a sublingual fentanyl formulation for managing breakthrough pain in cancer patients; ALLELOCK, an antihistamine for various allergic conditions; and CONIEL, a calcium channel blocker prescribed for hypertension and angina. Kyowa Kirin also provides a range of advanced biological and specialized treatments. These encompass Crysvita, a recombinant human monoclonal IgG1 antibody targeting fibroblast growth factor 23, and blood-related therapies like ESPO (human erythropoietin), NESP (an erythropoiesis stimulating agent), and GRAN (a human colony-stimulating factor). Further products in its lineup address diverse medical needs: G-LASTA/Peglasta/Neulasta for chemotherapy-induced febrile neutropenia; LEUNASE for acute lymphoblastic leukemia; LUMICEF, a biological treatment for moderate to severe plaque psoriasis; Moventig, a mu-opioid receptor antagonist for opioid-induced constipation; Nouriast/Nourianz, an adenosine receptor antagonist for Parkinson's disease; and ORKEDIA, an oral calcimimetics agent. Other significant offerings are PecFent, a nasally administered spray; POTELIGEO, a humanized monoclonal antibody targeting CC chemokine receptor 4; REGPARA for secondary hyperparathyroidism; Romiplate/Nplate, a recombinant protein promoting platelet production; and SANCUSO for managing nausea and vomiting. Beyond its current offerings, Kyowa Kirin is actively involved in pipeline development, notably through a strategic collaboration with Amgen Inc. for the joint development and commercialization of KHK4083. This Phase 3-ready, fully human anti-OX40 monoclonal antibody is being developed to treat atopic dermatitis. Established in Tokyo, Japan, in 1949, the company changed its name from Kyowa Hakko Kirin Co., Ltd. to Kyowa Kirin Co., Ltd. in June 2019. It operates as a subsidiary of Kirin Holdings Company, Limited.
Harga Saham
$15.32
Modal Pasaran
$8.02B
Perubahan (1 hari)
0.88%
Perubahan (1 tahun)
2.20%
Negara
JP
Perdagangan Kyowa Kirin Co., Ltd. (4151)
Kategori
Healthcare
Nisbah P/E bagi Kyowa Kirin Co., Ltd. (4151)
Nisbah P/E pada October 2026 TTM: 14.82
Menurut laporan kewangan dan harga saham terkini Kyowa Kirin Co., Ltd., nisbah P/E semasa (TTM) ialah 14.82. Pada akhir 2024, syarikat mempunyai nisbah P/E sebanyak 21.01.
Sejarah nisbah P/E bagi Kyowa Kirin Co., Ltd. dari 2001 hingga 2026
Nisbah P/E pada akhir setiap tahun
| Tahun | Nisbah P/E | Ubah |
|---|---|---|
| 2026 (TTM) | 14.82 | -24.91% |
| 2025 | 19.73 | -6.09% |
| 2024 | 21.01 | 33.89% |
| 2023 | 15.69 | -48.20% |
| 2022 | 30.30 | -5.84% |
| 2021 | 32.18 | 0.12% |
| 2020 | 32.14 | -12.62% |
| 2019 | 36.78 | 78.93% |
| 2018 | 20.56 | -26.05% |
| 2017 | 27.80 | -41.32% |
| 2016 | 47.37 | 34.58% |
| 2015 | 35.20 | -10.00% |
| 2014 | 39.11 | 85.42% |
| 2013 | 21.09 | 9.62% |
| 2012 | 19.24 | -7.75% |
| 2011 | 20.86 | -2.79% |
| 2010 | 21.46 | -66.44% |
| 2009 | 63.93 | 296.39% |
| 2008 | 16.13 | -53.66% |
| 2007 | 34.80 | 55.70% |
| 2006 | 22.35 | 14.16% |
| 2005 | 19.58 | -34.03% |
| 2004 | 29.68 | 14.74% |
| 2003 | 25.87 | -52.36% |
| 2002 | 54.29 | 46.46% |
| 2001 | 37.07 | 0.00% |
Nisbah P/E untuk syarikat serupa atau pesaing
| Syarikat | Nisbah P/E | Perbezaan Nisbah P/E | Negara |
|---|---|---|---|
| 40.53 | 173.56% |
US
|
|
| 38.50 | 159.84% |
US
|
|
| 79.88 | 439.15% |
US
|
|
| 116.96 | 689.43% |
US
|
|
| 22.25 | 50.17% |
CH
|
Cara membaca nisbah P/E
Nisbah Harga/Perolehan (P/E) mengukur hubungan antara harga saham syarikat dan pendapatan sesaham.
P/E yang rendah tetapi positif menunjukkan syarikat menjana keuntungan tinggi berbanding dengan penilaian semasa dan mungkin dinilai rendah. P/E negatif yang tinggi (hampir 0) menunjukkan kerugian besar.
Syarikat dengan P/E melebihi 30 atau negatif biasanya dilihat sebagai "saham pertumbuhan", bermaksud pelabur menjangkakan pertumbuhan atau keuntungan masa depan.
Syarikat dengan P/E positif di bawah 10 biasanya dianggap sebagai "saham nilai", bermaksud syarikat sudah menguntungkan dan tidak dijangka berkembang pesat.